AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company’s immunology and inflammation portfolio.
Connecting Global Economies
Flash News
Summer House’s Danielle Olivera Welcomes First Baby 10 Weeks Early
For Suns’ Devin Booker, new number opens new chapter in search of better ending
Alan Greenspan, former US Fed Reserve chair, dies aged 100
Alan Greenspan, former chairman of the Fed, dies at age 100
Nicole Kidman Shares Father’s Day Shoutout to Ex Keith Urban
Argentina vs Austria live updates: World Cup 2026 game latest news with Messi poised to start
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
UK PM Starmer resigns as Britain faces its seventh leader in 10 years
The World Cup in Las Vegas: Pool parties, star-spangled dungarees and 480 cans of Tennent’s
FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
Monday, June 22, 2026